23.58 USD
-0.87 (-3.56%)
23.58 USD
0 (0%)
CPRX gets a fundamental rating of 8 out of 10. The analysis compared the fundamentals against 525 industry peers in the Biotechnology industry. CPRX gets an excellent profitability rating and is at the same time showing great financial health properties. CPRX has both an excellent growth and valuation score. This means it is growing and it is still cheap. This is a rare combination! This makes CPRX very considerable for value and growth and quality investing!
1. Profitability
1.1 Basic Checks
- CPRX had positive earnings in the past year.
- CPRX had a positive operating cash flow in the past year.
- CPRX had positive earnings in each of the past 5 years.
- In the past 5 years CPRX always reported a positive cash flow from operatings.
1.2 Ratios
- Looking at the Return On Assets, with a value of 20.69%, CPRX belongs to the top of the industry, outperforming 97.14% of the companies in the same industry.
- With an excellent Return On Equity value of 23.65%, CPRX belongs to the best of the industry, outperforming 96.76% of the companies in the same industry.
- CPRX's Return On Invested Capital of 21.23% is amongst the best of the industry. CPRX outperforms 97.90% of its industry peers.
- The Average Return On Invested Capital over the past 3 years for CPRX is above the industry average of 18.07%.
- The 3 year average ROIC (20.37%) for CPRX is below the current ROIC(21.23%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 20.69% | ||
| ROE | 23.65% | ||
| ROIC | 21.23% |
ROA(3y)18.85%
ROA(5y)22.43%
ROE(3y)22.87%
ROE(5y)26.38%
ROIC(3y)20.37%
ROIC(5y)19.67%
1.3 Margins
- CPRX's Profit Margin of 37.64% is amongst the best of the industry. CPRX outperforms 96.76% of its industry peers.
- CPRX's Profit Margin has been stable in the last couple of years.
- Looking at the Operating Margin, with a value of 44.78%, CPRX belongs to the top of the industry, outperforming 99.43% of the companies in the same industry.
- CPRX's Operating Margin has improved in the last couple of years.
- With an excellent Gross Margin value of 85.68%, CPRX belongs to the best of the industry, outperforming 88.38% of the companies in the same industry.
- CPRX's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 44.78% | ||
| PM (TTM) | 37.64% | ||
| GM | 85.68% |
OM growth 3Y2.16%
OM growth 5Y5%
PM growth 3Y5.91%
PM growth 5Y1.34%
GM growth 3Y0.61%
GM growth 5Y0.11%
2. Health
2.1 Basic Checks
- CPRX has a Return on Invested Capital (ROIC), which is well above the Cost of Capital (WACC), which means it is creating value.
- The number of shares outstanding for CPRX has been increased compared to 1 year ago.
- Compared to 5 years ago, CPRX has more shares outstanding
- CPRX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
- An Altman-Z score of 16.02 indicates that CPRX is not in any danger for bankruptcy at the moment.
- With an excellent Altman-Z score value of 16.02, CPRX belongs to the best of the industry, outperforming 86.67% of the companies in the same industry.
- CPRX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Altman-Z | 16.02 |
ROIC/WACC2.39
WACC8.88%
2.3 Liquidity
- A Current Ratio of 6.62 indicates that CPRX has no problem at all paying its short term obligations.
- CPRX's Current ratio of 6.62 is fine compared to the rest of the industry. CPRX outperforms 67.62% of its industry peers.
- CPRX has a Quick Ratio of 6.40. This indicates that CPRX is financially healthy and has no problem in meeting its short term obligations.
- CPRX has a better Quick ratio (6.40) than 66.29% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 6.62 | ||
| Quick Ratio | 6.4 |
3. Growth
3.1 Past
- The Earnings Per Share has grown by an impressive 45.76% over the past year.
- The Earnings Per Share has been growing by 34.29% on average over the past years. This is a very strong growth
- The Revenue has grown by 25.56% in the past year. This is a very strong growth!
- The Revenue has been growing by 36.89% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)45.76%
EPS 3Y52.41%
EPS 5Y34.29%
EPS Q2Q%20%
Revenue 1Y (TTM)25.56%
Revenue growth 3Y51.72%
Revenue growth 5Y36.89%
Sales Q2Q%15.31%
3.2 Future
- The Earnings Per Share is expected to grow by 26.80% on average over the next years. This is a very strong growth
- The Revenue is expected to grow by 11.21% on average over the next years. This is quite good.
EPS Next Y24.97%
EPS Next 2Y18.55%
EPS Next 3Y12.53%
EPS Next 5Y26.8%
Revenue Next Year19.48%
Revenue Next 2Y13.05%
Revenue Next 3Y11.23%
Revenue Next 5Y11.21%
3.3 Evolution
- Although the future EPS growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
- Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
4. Valuation
4.1 Price/Earnings Ratio
- Based on the Price/Earnings ratio of 13.71, the valuation of CPRX can be described as correct.
- CPRX's Price/Earnings ratio is rather cheap when compared to the industry. CPRX is cheaper than 96.95% of the companies in the same industry.
- CPRX is valuated rather cheaply when we compare the Price/Earnings ratio to 27.21, which is the current average of the S&P500 Index.
- A Price/Forward Earnings ratio of 12.81 indicates a correct valuation of CPRX.
- Based on the Price/Forward Earnings ratio, CPRX is valued cheaply inside the industry as 96.76% of the companies are valued more expensively.
- When comparing the Price/Forward Earnings ratio of CPRX to the average of the S&P500 Index (25.98), we can say CPRX is valued rather cheaply.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 13.71 | ||
| Fwd PE | 12.81 |
4.2 Price Multiples
- Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of CPRX indicates a rather cheap valuation: CPRX is cheaper than 98.48% of the companies listed in the same industry.
- Based on the Price/Free Cash Flow ratio, CPRX is valued cheaper than 97.71% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 12.35 | ||
| EV/EBITDA | 7.44 |
4.3 Compensation for Growth
- The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
- The excellent profitability rating of CPRX may justify a higher PE ratio.
- CPRX's earnings are expected to grow with 12.53% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.55
PEG (5Y)0.4
EPS Next 2Y18.55%
EPS Next 3Y12.53%
5. Dividend
5.1 Amount
- CPRX does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
CATALYST PHARMACEUTICALS INC / CPRX FAQ
What is the ChartMill fundamental rating of CATALYST PHARMACEUTICALS INC (CPRX) stock?
ChartMill assigns a fundamental rating of 8 / 10 to CPRX.
What is the valuation status for CPRX stock?
ChartMill assigns a valuation rating of 8 / 10 to CATALYST PHARMACEUTICALS INC (CPRX). This can be considered as Undervalued.
Can you provide the profitability details for CATALYST PHARMACEUTICALS INC?
CATALYST PHARMACEUTICALS INC (CPRX) has a profitability rating of 9 / 10.
What is the expected EPS growth for CATALYST PHARMACEUTICALS INC (CPRX) stock?
The Earnings per Share (EPS) of CATALYST PHARMACEUTICALS INC (CPRX) is expected to grow by 24.97% in the next year.